Xiaoxian (Bill) Li, MD, PhD

Role

Pathology
Specialty

Breast Cancer
Research Program

Cell and Molecular Biology
Practicing Since

2011

Background

Xiaoxian (Bill) Li, MD, PhD, is Professor and serves as Director of Breast Pathology and Director of Immunohistochemistry Laboratory in the Department of Pathology and Laboratory Medicine of Emory University School of Medicine. Board certified in clinical and anatomic pathology, Dr. Li specializes in breast pathology.

Dr. Li is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University. He serves as co-chair of the Faculty Affair Committee for the Emory University School of Medicine Asian Americans and Pacific Islanders affinity group. At the national level, he currently serves in multiple national committees for various organizations including College of American Pathologists, United States and Canadian Academy of Pathology, Food and Drug Administration and I-SPY Trial Pathology Working Group.

Dr. Li is a standing member of an American Cancer Society Grant Review Committee, and an ad hoc grant reviewer for National Institutes of Health, National Cancer Institute, Department of Defense, American Cancer Society grants and Breast Cancer Now, England.

Dr. Li has mentored numerous PhD and Master's students, residents, fellows and visiting scholars and has been frequently invited to give lectures at national/international conferences including the United States and Canadian Academy of Pathology and College of American Pathologists annual meetings.

Dr. Li received his Medical Degree from Beijing Medical University in Beijing, China. He obtained his PhD from The University of Maryland in College Park, Maryland. He completed his postdoctoral training as a Postdoctoral Associate in the Department of Pharmacology at Fox Chase Cancer Center in Philadelphia, Pennsylvania and then as a Research Associate in the Breast Center at Baylor College of Medicine in Houston, Texas. He completed his anatomic pathology/clinical pathology residency training at The Methodist Hospital in Houston and an oncological pathology fellowship and a breast pathology fellowship at UT MD Anderson Cancer Center in Houston, Texas.

Dr. Li's research interests focus on all aspects of breast diseases from benign to malignant neoplasms, particularly developing predictive markers in breast cancer and studying the mechanisms underlying tumor initiation, progression and metastasis.

Lab Website

Dr. Li has published numerous peer reviewed publications, review articles and book chapters. Two of his first authored and co-first authored papers on breast cancer stem cells (PMID: 18445819; 19666588) have been cited more than 1,000 times respectively per Web of Science.

Dr. Li serves as Section Editor of Breast Pathology for Archives of Pathology and Laboratory Medicine, the official journal of CAP. He also serves on the editorial board of Breast Cancer Research and Treatment, Clinical Breast Cancer and Human Pathology.

PubMed
ResearchGate

Titles & Roles

Professor, Department of Pathology and Laboratory Medicine

Emory University School of Medicine
Director of Breast Pathology

Emory University Hospital
Director of Immunohistochemistry Laboratory

Emory University Hospital
Co-Director, Anatomic Pathology Research, Department of Pathology and Laboratory Medicine

Emory University School of Medicine

Education & Training

Education

Fellowship, Pathology, 2013
MD Anderson Cancer Center
Fellowship, Anatomic Pathology & Clinical Pathology, 2012
MD Anderson Cancer Center
Residency, Pathology, 2011
The Methodist Hospital
Medical Education, , 1997
Beijing Medical University

Board Certifications

Anatomic Pathology
American Board of Pathology, 2013

Title/Journal	Authors	Publication Date
High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast cancer research and treatment	SJ Wood, Y Gao, JH Lee, J Chen, Q Wang, JL Meisel, X Li	01/05/2024
Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research. Histopathology	A Ly, V Garcia, KRM Blenman, A Ehinger, K Elfer, MG Hanna, X Li, DJE Peeters, R Birmingham, S Dudgeon, E Gardecki, R Gupta, J Lennerz, T Pan, J Saltz, KA Wharton, D Ehinger, B Acs, EMC Dequeker, R Salgado, BD Gallas	01/05/2024
Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff. Breast cancer research and treatment	D Ai, G Turashvili, SG Gjeorgjievski, Q Wang, AM Ewaz, Y Gao, T Nguyen, C Zhang, X Li	01/04/2024
Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	K Elfer, E Gardecki, V Garcia, A Ly, E Hytopoulos, S Wen, MG Hanna, DJE Peeters, J Saltz, A Ehinger, SN Dudgeon, X Li, KRM Blenman, W Chen, U Green, R Birmingham, T Pan, JK Lennerz, R Salgado, BD Gallas	01/04/2024
Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in African American and European American patients with TNBC. bioRxiv : the preprint server for biology	Q Zhu, A Balasubramanian, JR Asirvatham, DWB Piyarathna, J Kaur, N Mohamed, L Wu, M Chatterjee, S Wang, N Pourfarrokh, U Rasaily, Y Xu, J Zheng, D Jebakumar, A Rao, SH Chen, Y Li, E Chang, X Li, R Aneja, XH Zhang, A Sreekumar	31/03/2024
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer. The Journal of pathology	CA Jahangir, DB Page, G Broeckx, CA Gonzalez, C Burke, C Murphy, JS Reis-Filho, A Ly, PW Harms, RR Gupta, M Vieth, AI Hida, M Kahila, Z Kos, PJ van Diest, S Verbandt, J Thagaard, R Khiroya, K Abduljabbar, G Acosta Haab, B Acs, S Adams, JS Almeida, I Alvarado-Cabrero, F Azmoudeh-Ardalan, S Badve, NB Baharun, ER Bellolio, V Bheemaraju, KR Blenman, L Botinelly Mendonça Fujimoto, O Burgues, A Chardas, MCU Cheang, F Ciompi, LA Cooper, A Coosemans, G Corredor, FL Dantas Portela, F Deman, S Demaria, SN Dudgeon, M Elghazawy, C Fernandez-Martín, S Fineberg, SB Fox, JM Giltnane, S Gnjatic, PI Gonzalez-Ericsson, A Grigoriadis, N Halama, MG Hanna, A Harbhajanka, SN Hart, J Hartman, S Hewitt, HM Horlings, Z Husain, S Irshad, EA Janssen, TR Kataoka, K Kawaguchi, AI Khramtsov, U Kiraz, P Kirtani, LL Kodach, K Korski, G Akturk, E Scott, A Kovács, AV Laenkholm, C Lang-Schwarz, D Larsimont, JK Lennerz, M Lerousseau, X Li, A Madabhushi, SK Maley, V Manur Narasimhamurthy, DK Marks, ES McDonald, R Mehrotra, S Michiels, D Kharidehal, FUAA Minhas, S Mittal, DA Moore, S Mushtaq, H Nighat, T Papathomas, F Penault-Llorca, RD Perera, CJ Pinard, JC Pinto-Cardenas, G Pruneri, L Pusztai, NM Rajpoot, BL Rapoport, TT Rau, JM Ribeiro, D Rimm, A Vincent-Salomon, J Saltz, S Sayed, E Hytopoulos, S Mahon, KP Siziopikou, C Sotiriou, A Stenzinger, MA Sughayer, D Sur, F Symmans, S Tanaka, T Taxter, S Tejpar, J Teuwen, EA Thompson, T Tramm, WT Tran, J van der Laak, GE Verghese, G Viale, N Wahab, T Walter, Y Waumans, HY Wen, W Yang, Y Yuan, J Bartlett, S Loibl, C Denkert, P Savas, S Loi, E Specht Stovgaard, R Salgado, WM Gallagher, A Rahman	01/03/2024
NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer. bioRxiv : the preprint server for biology	LA Ridnour, WF Heinz, RY Cheng, AL Wink, N Kedei, M Pore, F Imtiaz, EL Femino, AL Gonzalez, L Coutinho, D Butcher, EF Edmondson, MC Rangel, RJ Kinders, S Lipkowitz, ST Wong, SK Anderson, DW McVicar, X Li, SA Glynn, TR Billiar, JC Chang, SM Hewitt, S Ambs, SJ Lockett, DA Wink	23/12/2023
Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients. bioRxiv : the preprint server for biology	LA Ridnour, RYS Cheng, WF Heinz, M Pore, AL Gonzalez, EL Femino, R Moffat, AL Wink, F Imtiaz, L Coutinho, D Butcher, EF Edmondson, MC Rangel, STC Wong, S Lipkowitz, S Glynn, MP Vitek, DW McVicar, X Li, SK Anderson, N Paolocci, SM Hewitt, S Ambs, TR Billiar, JC Chang, SJ Lockett, DA Wink	23/12/2023
Intraoperative assessment of axillary sentinel lymph nodes by telepathology. Breast cancer research and treatment	G Turashvili, SG Gjeorgjievski, Q Wang, A Ewaz, D Ai, X Li, SS Badve	01/12/2023
Initial interactions with the FDA on developing a validation dataset as a medical device development tool. The Journal of pathology	S Hart, V Garcia, SN Dudgeon, MG Hanna, X Li, KR Blenman, K Elfer, A Ly, R Salgado, J Saltz, R Gupta, E Hytopoulos, D Larsimont, J Lennerz, BD Gallas	01/12/2023
Rosai-Dorfman disease of the breast: a clinicoradiologic and pathologic study. Human pathology	Q Wang, K Bradley, M Zhang, S Li, X Li	01/11/2023
Comprehensive Clinical-Pathologic Assessment of Malignant Phyllodes Tumors: Proposing Refined Diagnostic Criteria. The American journal of surgical pathology	G Turashvili, Q Ding, Y Liu, L Peng, M Mrkonjic, H Mejbel, Y Wang, H Zhang, G Zhang, J Wang, S Wei, X Li	01/11/2023
Inflammatory Lesions of the Breast. Archives of pathology & laboratory medicine	G Turashvili, X Li	01/10/2023
Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer. Journal of clinical pathology	G Turashvili, Y Gao, DA Ai, AM Ewaz, SG Gjeorgjievski, Q Wang, TTA Nguyen, C Zhang, X Li	15/09/2023
Hot Topics in Breast Pathology. Archives of pathology & laboratory medicine	G Turashvili, X Li	01/09/2023
Low-grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients. Histopathology	G Lewis, N Fong, SG Gjeorgjievski, XB Li, Z Li, S Wei, CD Sturgis, C Wang, M Komforti, H Zhang, E Downs, X Cui, P McIntire, RS Hoda, JJ Rowe, A Sciallis, G Zhang	01/08/2023
Interferon-gamma is quintessential for NOS2 and COX2 expression in ER^- breast tumors that lead to poor outcome. Cell death & disease	RYS Cheng, LA Ridnour, AL Wink, AL Gonzalez, EL Femino, H Rittscher, V Somasundaram, WF Heinz, L Coutinho, MC Rangel, EF Edmondson, D Butcher, RJ Kinders, X Li, STC Wong, DW McVicar, SK Anderson, M Pore, SM Hewitt, TR Billiar, SA Glynn, JC Chang, SJ Lockett, S Ambs, DA Wink	11/05/2023
Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	T Khoury, M Rosa, A Nayak, R Karabakhtsian, O Fadare, Z Li, B Turner, Y Fang, A Kumarapeli, X Li, N Numbere, T Villatoro, JG Wang, S Sadeghi, K Attwood, A George, R Bhargava	01/02/2023
PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. Cell death & disease	C Garlapati, S Joshi, S Bhattarai, J Krishnamurthy, RC Turaga, T Nguyen, X Li, R Aneja	10/01/2023
Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy. ACS nano	L Zhu, Y Zhao, T Liu, M Chen, WP Qian, B Jiang, BG Barwick, L Zhang, TM Styblo, X Li, L Yang	22/11/2022
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	K Sun, Y Xu, L Zhang, P Niravath, J Darcourt, T Patel, BS Teh, AM Farach, C Guerrero, S Mathur, MA Sultenfuss, N Gupta, MR Schwartz, SL Haley, S Nair, X Li, TTA Nguyen, JD Butner, J Ensor, JA Mejia, Z Mei, EB Butler, SH Chen, EH Bernicker, JC Chang	14/10/2022
Updates on Lobular Neoplasms and Papillary, Adenomyoepithelial, and Fibroepithelial Lesions of the Breast. Archives of pathology & laboratory medicine	X Li, C Febres-Aldana, H Zhang, X Zhang, I Uraizee, P Tang	01/08/2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	C Yam, N Abuhadra, R Sun, BE Adrada, QQ Ding, JB White, EE Ravenberg, AR Clayborn, V Valero, D Tripathy, S Damodaran, BK Arun, JK Litton, NT Ueno, RK Murthy, B Lim, L Baez, X Li, AU Buzdar, GN Hortobagyi, AM Thompson, EA Mittendorf, GM Rauch, RP Candelaria, L Huo, SL Moulder, JT Chang	01/07/2022
Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms. Journal of medical imaging (Bellingham, Wash.)	K Elfer, S Dudgeon, V Garcia, K Blenman, E Hytopoulos, S Wen, X Li, A Ly, B Werness, MS Sheth, M Amgad, R Gupta, J Saltz, MG Hanna, A Ehinger, D Peeters, R Salgado, BD Gallas	01/07/2022
Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell death & disease	JD Butner, P Dogra, C Chung, J Ruiz-Ramírez, S Nizzero, M Plodinec, X Li, PY Pan, SH Chen, V Cristini, B Ozpolat, GA Calin, Z Wang	21/05/2022
Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers	V Garcia, K Elfer, DJE Peeters, A Ehinger, B Werness, A Ly, X Li, MG Hanna, KRM Blenman, R Salgado, BD Gallas	17/05/2022
Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast cancer research and treatment	TTA Nguyen, LM Postlewait, C Zhang, JL Meisel, R O'Regan, S Badve, K Kalinsky, X Li	01/04/2022
Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score. Frontiers in medicine	H Li, J Wang, Z Li, M Dababneh, F Wang, P Zhao, GH Smith, G Teodoro, M Li, J Kong, X Li	01/01/2022
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. Clinical breast cancer	E Sakach, R O'Regan, J Meisel, X Li	01/12/2021
Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas. Human pathology	T Shen, L Wei, X Li, AV Parwani, Z Li	01/10/2021
Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell reports methods	K Su, Q Yu, R Shen, SY Sun, CS Moreno, X Li, ZS Qin	23/08/2021
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast cancer research and treatment	E Koca, PA Niravath, J Ensor, TA Patel, X Li, P Hemati, H Wong, W Qian, T Boone, J Zhao, PV Ramshesh, AL Cohen, A Murthy, S Nair, JG Darcourt, A Belcheva, VG Kaklamani, JCN Chang	01/07/2021
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	R Bhargava, NN Esposito, SM OʹConnor, Z Li, BM Turner, I Moisini, A Ranade, RP Harris, DV Miller, X Li, H Moosavi, BZ Clark, AM Brufsky, DJ Dabbs	01/01/2021
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. PloS one	L Huang, R Bommireddy, LE Munoz, RN Guin, C Wei, A Ruggieri, AP Menon, X Li, M Shanmugam, TK Owonikoko, SS Ramalingam, P Selvaraj	01/01/2021
Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database. Asian Pacific journal of cancer prevention : APJCP	Y Guo, CA Arciero, R Jiang, M Behera, L Peng, X Li	01/12/2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology, research and practice	J Zhao, U Krishnamurti, C Zhang, J Meisel, Z Wei, A Suo, R Aneja, Z Li, X Li	01/11/2020
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast cancer research and treatment	J Zhao, J Meisel, Y Guo, R Nahta, KL Hsieh, L Peng, Z Wei, R O'Regan, X Li	01/10/2020
Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center. Breast cancer research and treatment	Z Ma, CA Arciero, TM Styblo, H Wang, MA Cohen, X Li	01/10/2020
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast cancer research and treatment	AC Li, J Zhao, C Zhao, Z Ma, R Hartage, Y Zhang, X Li, AV Parwani	01/04/2020
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical breast cancer	JL Meisel, J Zhao, A Suo, C Zhang, Z Wei, C Taylor, R Aneja, U Krishnamurti, Z Li, R Nahta, R O'Regan, X Li	01/02/2020
The clinical significance of metastatic breast carcinoma to intramammary lymph node. The breast journal	T Khoury, Y Fang, R Karabakhtsian, M Mokhtar Desouki, A Nayak, M Hanna, S Sanati, X Peng, L Yan, X Li, O Fadare, C Ambrosone, N Jabbour, C Gaudioso	01/02/2020
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast cancer research : BCR	TA Patel, JE Ensor, SL Creamer, T Boone, AA Rodriguez, PA Niravath, JG Darcourt, JL Meisel, X Li, J Zhao, JG Kuhn, RR Rosato, W Qian, A Belcheva, MR Schwartz, VG Kaklamani, JC Chang	02/09/2019
Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. Clinical breast cancer	E Paplomata, A Zelnak, CA Santa-Maria, Y Liu, K Gogineni, X Li, CS Moreno, Z Chen, V Kaklamani, RM O'Regan	01/06/2019
The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers. American journal of clinical pathology	F Schneider, Y Jin, K Van Smaalen, EH Gulbahce, RE Factor, X Li	02/04/2019
Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases. The breast journal	C Neely, S You, PM Mendoza, R Aneja, AA Sahin, X Li	01/11/2018
Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clinical breast cancer	J Meisel, C Zhang, C Neely, P Mendoza, S You, T Han, Y Liu, AA Sahin, R O'Regan, X Li	01/10/2018
Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast. American journal of clinical pathology	Y Hou, DL Zynger, X Li, Z Li	01/08/2017
Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients. Clinical breast cancer	X Li, J Yang, U Krishnamurti, L Huo, KC Ward, R O'Regan, L Peng	01/08/2017
High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Human pathology	X Li, B Wei, C Sonmez, Z Li, L Peng	01/08/2017
Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute	B Dave, DD Gonzalez, ZB Liu, X Li, H Wong, S Granados, NE Ezzedine, DH Sieglaff, JE Ensor, KD Miller, M Radovich, A KarinaEtrovic, SS Gross, O Elemento, GB Mills, MZ Gilcrease, JC Chang	01/06/2017
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American journal of clinical pathology	X Li, CS Wetherilt, U Krishnamurti, J Yang, Y Ma, TM Styblo, JL Meisel, L Peng, MT Siddiqui, C Cohen, R Aneja	01/10/2016
An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes & development	M Jennis, CP Kung, S Basu, A Budina-Kolomets, JI Leu, S Khaku, JP Scott, KQ Cai, MR Campbell, DK Porter, X Wang, DA Bell, X Li, DS Garlick, Q Liu, M Hollstein, DL George, ME Murphy	15/04/2016
Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature. Gynecologic oncology reports	CH Han, X Li, N Khanna	01/01/2016
Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. International journal of clinical and experimental pathology	X Li, MR Schwartz, J Ro, CR Hamilton, AG Ayala, LD Truong, QJ Zhai	01/01/2014

Awards

#3 the most cited papers in Clinical Breast Cancer since 2018 (PMID: 30846407), 2022
Emory Millipub Club Award, Emory University School of Medicine, 2018, 2022
Award for Outstanding Contributions to Clinical Science Research, Department of Pathology and Laboratory Medicine, Emory University, 2019
Fellow Research Award ($10,000), Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center, 2012-2013
Poster Presentation Competition 2rd Place, 89th Texas Society of Pathologists Annual Meeting, Galveston, TX, 2010
Poster Presentation Competition 3rd Place, 88th Texas Society of Pathologists Annual Meeting, Austin, TX, 2009
Podium Presentation Competition 2nd Place, 87th Texas Society of Pathologists Annual Meeting, Houston, TX, 2008
Department of Defense Breast Cancer Training Grant, Fox Chase Cancer Center, 2002-2004
Eugenie Clark Summer Research Fellowship, University of Maryland, 2001
College of Life Sciences Travel Award, University of Maryland, 2000 & 2001
Jacob K. Goldhabor Travel Award, University of Maryland, 2000

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.